Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer (NCT06801236)
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)
🩺 Plain-English Summary (8th-Grade Level)
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Who can join: Review the eligibility criteria below.
Location: University of California San Diego, Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of California San Diego, Moores Cancer Center — La Jolla, California
- Moffitt Cancer Center, Tampa — Tampa, Florida
- University of Maryland, Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Harvard Medical School-Massachusetts General Hospital — Boston, Massachusetts
- M Health Fairview Clinics and Surgery Center — Minneapolis, Minnesota
- Xcancer (Urology Cancer Center) — Omaha, Nebraska
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- Fujian Cancer Hospital — Fuzhou, Fujian
📞 Contact the Study Coordinator
Phone: 86-13817816369
Email: derek.yang@acerand.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer (Adenocarcinoma)
- Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity — Toronto, Ontario
- 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy — Toronto, Ontario
- PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer — Winnipeg, Manitoba
- Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months. — Gatineau, Quebec
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide — Duarte, California
- Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer — Philadelphia, Pennsylvania
Explore by condition: All Prostate Cancer (Adenocarcinoma) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.